Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer
Latest Information Update: 12 Sep 2023
At a glance
- Drugs Letrozole (Primary) ; Ribociclib (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Paclitaxel
- Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms NEOLBC
- 04 Mar 2022 Planned End Date changed from 1 Aug 2025 to 1 Aug 2027.
- 04 Mar 2022 Planned primary completion date changed from 1 Dec 2021 to 4 Mar 2026.
- 22 Jul 2021 Planned primary completion date changed from 1 Jan 2021 to 1 Dec 2021.